CN1092680A - The Chinese medicine anticancer powdered injection - Google Patents
The Chinese medicine anticancer powdered injection Download PDFInfo
- Publication number
- CN1092680A CN1092680A CN93118007A CN93118007A CN1092680A CN 1092680 A CN1092680 A CN 1092680A CN 93118007 A CN93118007 A CN 93118007A CN 93118007 A CN93118007 A CN 93118007A CN 1092680 A CN1092680 A CN 1092680A
- Authority
- CN
- China
- Prior art keywords
- anticancer
- mice
- medicine
- injection
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of preparation method of Chinese medicine anticancer powdered injection, 1 part of Scolopendra and 1.5～2 portions of Flos Loniceraes through water extraction, are concentrated, precipitate with ethanol, sterilization, ingredients, dry and make, use for the clinical vein drop.It is good that this medicine is suffered from curative effect to multiple cancer such as the esophageal carcinoma, gastric cancer, hepatocarcinoma, leukemia, and the cure rate height prolongs life span, improves life quality, safety, no pain, low toxic and side effects.
Description
The present invention relates to a kind of Chinese medicine anticancer powdered injection, be specially adapted to treat the esophageal carcinoma, kinds of tumors diseases such as gastric cancer, hepatocarcinoma, leukemia.
Cancer is one of two big persistent ailments that threaten human life's health.Have every year the million people of healing to die from cancer according to statistics China, morbidity and death toll are in rising trend.Because at present cancer can not early discovery and is made a definite diagnosis, and makes to treat to be difficult to reach good effect.Reaching the healing result, according to existing medicine and method, is exactly to prolong life cycle, improves the life quality aspect, and effect is also unsatisfactory.Though but the operative therapy tumor resection, postoperative also has the possibility of transfer, and is not suitable for tumor treatment such as the esophageal carcinoma, hepatocarcinoma, leukemia; But X-ray therapy killing tumor cells, but normal structure is caused corresponding injury, produce very big side effect, the cyclophosphamide that embolic chemotherapy is commonly used is though 5-fluorouracil, match have definite curative effect for medicines such as group and amycin, can play mitigation, but because of its to the leukocytic powerful toxic and side effects of killing and wounding and human body being produced, the fair cancer of some body constitution is suffered from become weak within a short period of time, even have to interrupt chemotherapy, just do not dare to inquire and the not good enough cancer of some body constitution is suffered from beginning.Herbal treatment comes into one's own with the advantage of its low toxic and side effects recently and welcomes, but lacks generally acknowledged anticancer preparation safely and effectively clinically.
The object of the present invention is to provide a kind ofly to be adapted to cancers such as the esophageal carcinoma, gastric cancer, hepatocarcinoma, leukemia to suffer from curative effects good, prolong life span, improve life quality, the Chinese medicine powder injection of safety, low toxic and side effects.
Technical solution of the present invention is made up of Scolopendra, Flos Lonicerae two flavor Chinese medicines, with 1 part of Scolopendra and 1.5～2 parts of (weight) Flos Loniceraes through water extraction, concentrated, precipitate with ethanol, sterilization, preparation, drying and make.
Product of the present invention is made by the following method.
One, the processing of crude drug and dosage: Scolopendra decaptitate foot, Flos Lonicerae decontamination, divide 1 part of Scolopendra of another name 1.5～2 parts of (weight) Flos Loniceraes.
Two, the extraction of Scolopendra, Flos Lonicerae:
1, the crude drug water that takes by weighing is decocted twice.Add for the first time 14 times of crude drug weight deionized waters and soaked 1 hour, decocted 1.5 hours, filter; Decocted 1 hour with 10 times of amount deionized waters for the second time, filter.
2, merge twice filtrate, be concentrated into that relative density is 1.01～1.30 under 50 ℃ of temperature, wait to be chilled to 5-50 ℃, slowly adding 95% ethanol limit edged fully stirs, make to contain alcohol amount and reach 40～90%, static 24 hours, get supernatant, decompression recycling ethanol is not to there being the alcohol flavor, and obtaining relative density is 1.01～1.30(60 ℃ of survey) extractum.
3, add appropriate amount of deionized water in the extractum, transfer PH to 5～8, fully stir with 20%NaOH solution, be heated to and boil, placed 24 hours, filter, it is 1.01～1.40(80 ℃ of survey that collection filtrate is concentrated into relative density), wait to be chilled to 5～40 ℃ and add 95% ethanol, make to contain the alcohol amount and reach 50～90%, static 48 hours, get supernatant, decompression recycling ethanol, making relative density is 1.10～1.40(85 ℃ of survey) Scolopendra, Flos Lonicerae extract.
Three, the preparation of semi-finished product medicinal liquid
1, adds appropriate amount of deionized water in the extract, transfer PH to 5～9 with 20%NaOH solution, fully stir, add 5 ‰ active carbons, boil, and keep little and boiled 5～90 minutes, put coldly, squeeze into cold-storage jar again, cold preservation 72 hours, filter, filtrate 0.1MPa sterilization 10～90 minutes is put cold, squeeze into cold-storage jar again, cold preservation 120 hours filters, filtrate 0.1MPa sterilization 10～90 minutes, put and be chilled to 5～40 ℃, transfer PH to 4.0～10 with 20%NaOH solution, being concentrated into relative density is 1.01～1.35(50～60 ℃ surveys), 0.1MPa sterilization 10～90 minutes.
Four, the preparation of finished powder injection, semi-finished product can be made the finished powder injection with spray drying and two kinds of methods of lyophilization.
1, adopt spray drying method for preparation: all pipelines that will contact with the semi-finished product medicinal liquid, container, medium carry out aseptic process.The degerming of semi-finished product medicinal liquid is filtered, and jar enters the spray tower before tower, and tower top temperature is 30～300 ℃, and column bottom temperature is 20～250 ℃, and the medicinal liquid flow velocity is 1～100 liter/hour, makes sterilized powder, packing, and packing gets the finished powder injection.
2, the also available freeze-drying preparation of product of the present invention, the plate temperature is 0～-80 ℃ during lyophilizing, and products temperature is 0～-100 ℃, and condensation temperature is 0～-140 ℃.
The anxious poison experiment of injectable powder of the present invention is as follows:
Get 50 of Kunming mouses, body weight 18 ± 2g, male and female half and half, random packet, be divided into five groups, every group 10,, adopt intravenous administration by 5 dosage groups of geometric progression design, the adjacent doses ratio is 1: 0.8, the volume of single administration is 0.2ml/10g, and the variation in 7 days is observed in the contamination back, presses improved method to calculate anxious malicious LD with the bandit
50Be 2510 ± 43mg/kg, can find out that from then on preparation of the present invention is a moderately toxic medicine, with chemotherapeutic cyclophosphamide (LD
50Being 300mg/kg, is high cytotoxic drug) to compare toxicity little, and its toxicity is 1/8.36 of cyclophosphamide.
Injectable powder long term toxicity test of the present invention is as follows:
One, experimental technique
(body weight 0.5～0.8kg), male and female half and half are observed a week, anosis rabbit and no abnormal rabbit to get 80 of rabbit.Be divided into four groups at random, every group 20, male and female half and half, be divided into large, medium and small three dosage groups and blank according to group, three dosage groups are 1200mg/kg, 600mg/kg, 300mg/kg, matched group gives with the volume normal saline, 12 weeks of successive administration, observe Signs every day after the administration, outward appearance, behavior, food consumption quantity, survey body weight, routine blood test, hepatic and renal function before feces situation, the medicine, in the medicine, behind the medicine respectively, sick inspection ten important organs (heart, liver, spleen, lung, kidney, brain, intestinal, adrenal gland, gonad, stomach) behind the medicine
Two, experimental result
(1) ordinary circumstance
Administration diarrhea occurs after two weeks, and the back recovery of three weeks is normal, and administration group and matched group rabbit vegetative activity are normal, and hair color is glossy, and does not have depilation phenomenon.
(2) the body weight situation sees Table 1
Table 1, the long poison of anticancer powdered injection are tested the influence to the rabbit body weight
Body weight (kg) after body weight (kg) administration six all body weight (kg) administrations before the group number of animals medicine
Begin to finish (X ± SD) (X ± and SD) (X ± SD)
Heavy dose of 20 18 0.64 ± 0.19 1.15 ± 0.27 1.62 ± 0.41
Middle dosage 20 20 0.72 ± 0.18 1.20 ± 0.30 1.59 ± 0.38
Low dose of 20 20 0.64 ± 0.15 1.08 ± 0.29 1.52 ± 0.31
Normal saline 20 20 0.78 ± 0.16 1.23 ± 0.35 1.70 ± 0.31
Annotate: tested for 8 weeks, during 10 weeks, each dead 1 (in heavy dose of group)
By there was no significant difference between visible administration cross-reference group of table 1 and administration group.（P＞0.05）。
(3) influence to the rabbit routine blood test sees Table 2
( X±SD)
Low dose of anticancer powder pin normal saline matched group
Before the medicine behind medication six all medicines before the medicine behind medication six all medicines
5.8±0.4 5.3±0.3 5.2±0.4 5.3±0.5 5.2±0.3 5.7±0.5
×10
12×10
12×10
12×10
12×10
12×10
12
100.5±9.2 110.6±8.7 109.5±9.4 99.7±8.4 105±9.4 103±8.7
43.5±4.5 40.6±6.1 39.9±4.9 44.5±5.6 42.7±5.8 43.6±6.2
×10
9×10
9×10
9×10
9×10
9×10
9
9.2±0.5 9.8±0.4 10.1±0.6 9.4±0.7 10.1±0.5 9.3±0.8
×10
9×10
9×10
9×10
9×10
9×10
9
39.5±4.4 40.1±5.1 39.7±3.8 40.5±6.0 39.4±5.7 58.6±4.3
3.1±0.2 3.7±0.3 3.8±0.4 3.9±0.4 3.8±0.3 4.1±0.4
2.8±0.05 2.7±0.04 2.6±0.05 2.4±0.04 2.7±0.03 2.8±0.05
55.7±6.4 56.4±3.9 59.1±5.1 59.7±6.1 53.6±7.4 55.3±6.8
2.8±0.4 2.6±0.3 2.7±0.4 2.8±0.3 3.1±0.3 3.0±0.2
Other respectively organize physiochemical indice except that erythrocyte (heavy dose of group) as seen from Table 2, there was no significant difference between matched group and administration group (P＞0.05).The heavy dose of group of anticancer powder pin (1200mg/kg) medication six weeks back red blood cell decreased is reduced to following (4.0 ± 0.2) * 10 of normal value when medication finishes
12With the matched group ratio significant difference (P＜0.05) is arranged.
(4), the long poison experiment of anticancer powdered injection sees Table 4 to the influence of liver, renal function
The long poison of table 4 anticancer powdered injection is to the influence (n=20) of liver, renal function
BUN(nmol/L)
Behind the preceding medication six all medicines of medicine
4.74±0.29 4.83±0.41 4.95±0.50
4.94±0.38 5.15±0.52 5.01±0.41
4.87±0.34 4.94±0.38 4.90±0.47
4.50±0.41 4.75±0.60 4.94±0.37
Hepatic and renal function there was no significant difference (P＞0.05) before experimental result shows administration group and matched group medicine, behind the medicine
Notes: routine blood test detects, and liver, renal function are measured and adopted the method for national Clinical Laboratory rule of operation and clinical biochemical check to carry out, BUN acetyl-oxime determination of color, and analytical unit is nmol/L, and GPT, GOT adopt colorimetric method for determining, and analytical unit is nmol/L.
The anticancer powdered injection pharmacodynamic experiment
One, experiment material
(1) experimental drug
Anticancer powdered injection: Harbin No.2 Traditional Chinese Pharmacetical Plant produces, lot number 920527; Cyclophosphamide: Shanghai No.12 Pharmaceutical Factory produces, lot number 910308; Tegafur: Jinan pharmaceutical factory produces, lot number 900621.
(2) animal
615 mouse inbred liness: provide by Chinese medical courses in general institute Blood Research Institute; Crust is than being mice: provided by animal medicine portion of Harbin Medical University; Kunming mouse: workers and peasants' animal cultivation factory provides by Harbin.
(3) tumor strain
Leukemia L
615Mice, ehrlich carcinoma (EAC) mice, murine sarcoma S
180Provide by Chinese Academy of Medical Sciences's Blood Research Institute, institute of oncology, Tianjin, Heilongjiang Traditional Chinese Medicine university institute of Chinese materia medica respectively successively.
Two, experimental technique and result
(1) anticancer powdered injection is to mice S
180Influence
Get mice (Kunming kind), body weight 20 ± 2g, the male and female dual-purpose, by " screening rules in the national antineoplastic agent object " method [1] inoculation, the tumor source is the inoculation Ninth Heaven, the S that tumor growth is good
180A takes out ascites, by 1: 4 dilution proportion, makes the tumor cell suspension, (5 * 10 with sterile saline
6It is subcutaneous that cell/ml) is inoculated in the right side of mice axillary fossa with every of 0.2ml/ respectively, random packet behind the 24h, grouping is administered once every day, intraperitoneal injection by way of, the intravenous administration approach is 15 days, put to death mice next day after the drug withdrawal, take out the tumor piece and weigh, calculate tumour inhibiting rate, the results are shown in Table 1, table 2.
The quiet notes of table 1 different pharmaceutical are to mice S
180Influence
Heavy (g) tumour inhibiting rate P of the average tumor of dosage number of animals value
Group (mg/kg) (only) (X ± SD) (%)
Anticancer powdered injection 1,200 60 0.52 ± 0.08 55.93＜0.01
Cyclophosphamide 50 60 0.44 ± 0.06 62.71＜0.01
Tegafur 240 60 0.50 ± 0.07 57.63＜0.01
Normal saline is with volume 105 1.18 ± 0.11
Table 2
The different pharmaceutical lumbar injection is to S
180The influence of mice
Heavy (g) tumour inhibiting rate P of the average tumor of dosage number of animals value
Group (mg/kg) (only) (X ± SD) (%)
Anticancer powdered injection 1,800 60 0.64 ± 0.07 45.00＜0.05
Cyclophosphamide 75 60 0.58 ± 0.06 52.07＜0.01
Tegafur 300 60 0.56 ± 0.08 53.72＜0.01
Normal saline is with volume 105 1.21 ± 0.13
Notes table 1 is respectively organized weight loss 14.8 ± 2.1% behind the mice medicine, and each group of table 2 descends 10.8 ± 0.9%
By table 1,2 as can be seen, anticancer powdered injection is intraperitoneal injection no matter, and still quiet notes administration all has antagonism mice S
180Effect, and be the dose-effect positive correlation.With matched group significant difference (P＜0.05) is arranged.（P＜0.01）。
(2) anticancer powdered injection is to the influence of EAC mice
Get crust than being mice, body weight 20 ± 2g, male and female dual-purpose, method inoculation by " screening rules in the national antineoplastic agent object ", ascites is taken out for 7 days good EAC mices of tumor growth of inoculation in the tumor source, makes tumor cell suspension (5 * 10 with the normal saline of sterilization by 1: 4 dilution proportion
6Cell/ml), only be inoculated in the mouse peritoneal with 0.2ml/ respectively, random packet behind the 24h, administration is the same, and put to death mice next day after the drug withdrawal, collects whole ascites, with TPCV method (2), obtains suppression ratio, the results are shown in Table 3, table 4.
The quiet notes of table 3 different pharmaceutical are to the influence of EAC mice
Dosage number of animals average T PCV (ml) tumour inhibiting rate P value
Group (mg/kg) (only) (X ± SD) (%)
Anticancer powdered injection 1,200 60 1.58 ± 0.44 66.24＜0.01
Cyclophosphamide 50 60 1.31 ± 0.40 72.01＜0.01
Tegafur 240 60 1.49 ± 0.51 68.16＜0.01
Normal saline is with volume 105 4.68 ± 0.62
Annotate: each organizes weight loss 6.8 ± 0.31% after the mice administration
Table 4 different pharmaceutical abdomen is annotated the influence to the EAC mice
Dosage number of animals average T PCV (ml) tumour inhibiting rate P value
Group (mg/kg) (only) (X ± SD) (%)
Anticancer powdered injection 1,800 60 1.87 ± 0.49 67.14＜0.01
Cyclophosphamide 75 60 1.90 ± 0.38 66.61＜0.01
Tegafur 300 60 2.01 ± 0.41 63.09＜0.01
Normal saline is with volume 105 5.69 ± 0.74
Annotate: each organizes weight loss 14.21 ± 1.50% behind the mice medicine.
The result shows that the propagation that the anticancer powdered injection abdomen is annotated EAC mouse peritoneal cancerous cell has stronger inhibitory action, and its action intensity has the trend greater than quiet notes.
(3) anticancer powdered injection is to L
615The influence of mice
Getting 615 is purebred mice, body weight 20 ± 2g, and the male and female dual-purpose, by the method inoculation of " screening rule in the national antineoplastic agent object ", the tumor source is 5 days well-grown L of inoculation
615Mice under aseptic condition, take out spleen, is cut 50mg, use sterile saline homogenate, and the adjustment tumor cell is 5 * 10
5/ ml only is inoculated in the mouse peritoneal with 0.2ml/ respectively, random packet behind the 24h, and successive administration 7 days is observed the mice time-to-live and is calculated increase in life span after the drug withdrawal, the results are shown in Table 5, table 6.
The quiet notes of table 5 different pharmaceutical L
615The influence of mice
The dosage number of animals time-to-live (my god) increase in life span P value
Group (mg/kg) (only) (X ± SD) (%)
Anticancer powdered injection 1,200 60 10.98 ± 0.81 58.90＜0.05
Cyclophosphamide 50 60 11.94 ± 0.74 72.79＜0.01
Tegafur 240 60 7.41 ± 0.64 7.24＜0.05
Normal saline is with volume 105 6.91 ± 0.75
Annotate: each organizes weight loss 12.6 ± 1.5% after the mice medication
The result shows that anticancer powdered injection is to leukemia L
615Mice has the prolongation vital action.
Table 6 different pharmaceutical abdomen is annotated L
615The influence of mice
The dosage number of animals time-to-live (my god) increase in life span P value
Group (mg/kg) (only) (X ± SD) (%)
Anticancer powdered injection 1,800 60 10.21 ± 0.64 54.93＜0.05
Cyclophosphamide 75 60 11.08 ± 0.70 68.13＜0.01
Tegafur 300 60 7.00 ± 0.44 6.22＜0.05
Normal saline is with volume 105 6.59 ± 0.58
The result shows that anticancer powdered injection is to mice transplanted tumor S
180, EAC all has inhibitory action, and can prolong L
615The life of mice, it suppresses effect and prolongs vital action that the dose-effect linear relationship is all arranged, and is an anticancer inhibitor of Chinese medicine that effect is stronger.
Annotate: the screening rules are the 374th page in [1] national antineoplastic agent object.
[2] harvest-pharmaceutical journal 105(27 in the village in the Japan): 188,1983
This Chinese medicine anticancer powdered injection shows through pharmacological evaluation, adopts the intravenous drip administration, to mice S
180Tumour inhibiting rate be 55.93%, cyclophosphamide is 62.71% on the same group, Tegafur is 57.63%; To the EAC(ehrlich carcinoma) tumour inhibiting rate be 66.24%, cyclophosphamide is 72.01%, Tegafur is 68.16%; To L
615The increase in life span of mice is 58.90%, and cyclophosphamide is 72.79%, and furan fluorine urine is phonetic to be decided to be 7.24.As seen product curative effect of the present invention is near the cyclophosphamide of clinical first-selection, and Tegafur, and safety hang down toxic and side effects, can improve advanced carcinoma patient's life quality, prolong life span.
To 21 examples through pathological diagnosis, the cancer patient that the imageology diagnosis is made a definite diagnosis, do not have the end-stage patients that treat meaning belong to more, use medicine of the present invention, everyone 4～6 (2-3 gram) dilutes with 5% glucose 250-500 milliliter, intravenous drip, once a day, 14 days is a course of treatment, medication 1-3 course of treatment, can stop between per course of treatment medicine 7-10 days.After most cases were used this medicine, the mental status was improved, and appetite appetite increases, and pain and other subjective symptoms obviously alleviate, and have reduced patient's misery, and life quality improves a lot, and indivedual case lumps dwindle.Model case is as follows:
Patient's time * *, 65 years old, the man, the diagnosing primary hepatoma, twin-lock bone superior gluteal lymph node shifts, two pulmonary metastases, lymphonodi coeliaci shifts.Ye Geyi place, CT examination liver left and right sides occupying lesion, it respectively is 5.5 * 5.6cm and 7.8 * 7.1cm that B ultrasonic is measured.Patient's progressive emaciation, the anemia outward appearance, sclera does not have xanthochromia, and two lungs and heart do not have the bright positive of work disease of science, 6cm under the liver rib, 11cm under the xiphoid-process, air spots is sliding, and is harder, edge Tun, the swollen thing of 8 * 6cm size is touched on the umbilicus upper left side, and is harder, painless, no ascites symptoms.Medicine treatment of the present invention course of treatment (14 days, meter 27.5 grams) swollen thing of postabdomen obviously is reduced to 5.5 * 4.5cm, stops medicine and carries out medication second course of treatment (14 days, meter 42 grams) the swollen thing of swollen portion after ten days and dwindle slightly again.The medication phase does not have any untoward reaction, and the conscious good muscle power that reaches all has improvement.
Further specify technical solution of the present invention in conjunction with the embodiments.
Take by weighing dried Scolopendra 500 grams of the foot of decaptitating and decontamination Flos Lonicerae 750 grams, soaked 1 hour with the 19000ml deionized water, decocted 1.5 hours, filter, medicinal residues decocted 1 hour with the 14000ml deionized water, filtered.Merge filtrate twice, be concentrated into that relative density is 1.15 under 50 ℃ of temperature, be cooled to 10 ℃, slowly add 95% ethanol, the limit edged fully stirs, and makes to contain alcohol amount and reach 75%, static 24 hours, get supernatant, decompression recycling ethanol is not to there being the alcohol flavor, and obtaining relative density is 1.20(50 ℃) extractum.Add appropriate amount of deionized water, transfer PH to 6.80 with 20%NaOH, fully stir, be heated to and boil, placed 24 hours, filter, collect filtrate, being concentrated into relative density is 1.13(80 ℃ of survey), wait to be chilled to 10 ℃.Slowly add 95% ethanol, the limit edged fully stirs, and makes to contain alcohol amount and reach 85%, and static 48 hours, get supernatant, decompression recycling ethanol is not to there being the alcohol flavor, making relative density was 1.18(85 ℃ of survey) extractum.Add appropriate amount of deionized water, transfer PH to 7.0, add 3 gram activated carbon with 20%NaOH, stir evenly, heated and boiled, and keep little and boiled 20 minutes, cold preservation 72 hours filters, 0.1MPa sterilization 45 minutes, cold preservation 120 hours filters, and filtrate was 0.1MPa sterilization 30 minutes, put and be chilled to 10 ℃, but transfer PH to 7.6 with 20 NaOH, being concentrated into relative density is 1.10(85 ℃ of survey), 0.1MPa sterilize 30 minutes, semi-finished product are stand-by.All pipelines that contact with medicinal liquid, container, medium be through aseptic process, and semi-finished product are entered before the tower jar.System heats up, and makes column bottom temperature reach 100 ℃, and constant temperature 1 hour, begin to dust, sterilized powder 83.6 grams, packing gets 146 powder pins.
Claims (1)
1, a kind of preparation method of Chinese medicine anticancer powdered injection through water extraction, concentrates, precipitate with ethanol, and sterilization, ingredients, operation such as drying and making is characterized in that with 1 part of Scolopendra and 1.5～2 portions of Flos Loniceraes (weight).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93118007A CN1092680A (en) | 1993-09-22 | 1993-09-22 | The Chinese medicine anticancer powdered injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93118007A CN1092680A (en) | 1993-09-22 | 1993-09-22 | The Chinese medicine anticancer powdered injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1092680A true CN1092680A (en) | 1994-09-28 |
Family
ID=4992277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93118007A Pending CN1092680A (en) | 1993-09-22 | 1993-09-22 | The Chinese medicine anticancer powdered injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1092680A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9066974B1 (en) | 2010-11-13 | 2015-06-30 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
| US9095606B1 (en) | 2010-11-13 | 2015-08-04 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
| CN108992481A (en) * | 2018-10-12 | 2018-12-14 | 张金木 | For anti-curing oncoma and the Chinese medicine composition of osteomyelitis and preparation method thereof |
-
1993
- 1993-09-22 CN CN93118007A patent/CN1092680A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9066974B1 (en) | 2010-11-13 | 2015-06-30 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
| US9095606B1 (en) | 2010-11-13 | 2015-08-04 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
| CN108992481A (en) * | 2018-10-12 | 2018-12-14 | 张金木 | For anti-curing oncoma and the Chinese medicine composition of osteomyelitis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1163237C (en) | Anti-cancer therapy agent of arsenic hexoxide (AS4O6) of natural chemical substance and its pharmaceutical composition | |
| CN1272792A (en) | Herbal extract composition and method with immune-boosting capability | |
| CN1301666C (en) | Health food capable of raising immunity and its production process | |
| CN101032504A (en) | Application of liquiritin in medicines | |
| CN1686441A (en) | Chinese medicine capsule used for regulating immunity, its preparation method and use | |
| CN1098707C (en) | Medicinal composition containing algal protein polyose extract and extraction of algal protein polyose | |
| CN1839884A (en) | Fresh pilose antler freeze-drying powder preparation and traditional Chinese medicine formulation containing same and its uses | |
| CN1895337A (en) | Pharmaceutical use of Tangshen and Milkvetch root composition for improving late tumor patient life quality | |
| CN1092680A (en) | The Chinese medicine anticancer powdered injection | |
| CN1931255A (en) | Medicine for treating thrombocytopenia and anemia and its prepn process and quality control method | |
| CN1323675C (en) | Novel usage of chicory aqueous extract | |
| CN1709393A (en) | Chewing tablet of Taishan radix cynanchi bungei, its preparing method and use | |
| CN1053376C (en) | Antineoplastic Chinese medicine prepn and its prepn process | |
| CN1679658A (en) | Chinese medicine preparation for treating AIDS and process thereof | |
| CN1537564A (en) | Traditional chinese medicine prepns. for treating broad-spectrum cancers | |
| CN1094052C (en) | Anticancer goose blood preparation | |
| CN1150027C (en) | Medicine for curing tumor and its preparation method | |
| CN1421238A (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity | |
| CN1742783A (en) | Natural medicine preparatino for tonifying Qi strengthening body resistance and preparing method | |
| CN1298379C (en) | Medicine for curing malignant tumors of carcinoma of prostate, liver cancer and sarcoma | |
| CN1850107A (en) | Fatty cream composition for maligant splanchnocoele hydrops and its preparing method | |
| CN105560441B (en) | A kind of warm kidney is good for marrow, supplementing qi and nourishing yin, Chinese medicine composition of green blood hemostasis and preparation method thereof | |
| CN1957944A (en) | Application of yew amylose in pharmacy | |
| CN1513500A (en) | Liu-Wei-Bu-Xue granule for invigorating blood contg. six herbal medicines and its prepn. method | |
| CN101066291A (en) | Chinese medicine composition for transquilizing, warming Yang, benefiting Qi and nourishing heart and its prepn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |